Health Catalyst, Inc.
NASDAQ:HCATMedical - Healthcare Information Services
-$0.04 today
- Market cap
- $98.24M
- Beta
- 1.66
- P/E (TTM)
- -0.5
- EPS (TTM)
- -$3.65
Volume 0.27M
Average 1.24M
HCAT Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
Health Catalyst, Inc.NASDAQ: HCAT
Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Financing cash flow declines year over year
Q1 FY2026 financing cash flow of $4K (cash outflow) fell 99.9% year over year, ahead of the -258.1% change in trailing-twelve-month financing cash flow. Sequentially, it fell 99.1% from the prior quarter. Over 3 fiscal years it compounded at +348.5% a year.
Context
- Financing cash flow amounted to 75.8% of revenue in FY2025, up 26.3 pp from a year earlier.
- Financing cash flow increased in 2 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -99.9% holds above the trailing-twelve-month pace of -258.1%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (235.78M) USD
- Year-over-year change
- -255.4%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (235.78M) | -255.4% |
| FY2024 | 2024-12-31 | 151.75M | +5458.5% |
| FY2023 | 2023-12-31 | 2.73M | +204.5% |
| FY2022 | 2022-12-31 | (2.61M) | -101.0% |
| FY2021 | 2021-12-31 | 264.08M | — |
Financing Cash Flow vs competitors
How HCAT compares with its peers on the latest reported figures
- HCAT's LTM Mar 2026 financing cash flow of $231.07M is the 2nd largest of the 11 companies compared; the peer median is $23.66M.
- Its year-over-year change of -258.1% is the lowest of 11, against a peer median of +31.2%.
- Financing cash flow amounts to 76.4% of revenue for HCAT, versus a peer median of 105.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $442.16M | +4786.8% | +192.9% | 4611.1% | |
| LTM Mar 2026 | $231.07M | -258.1% | +348.5% | 76.4% | |
| LTM Mar 2026 | $94.16M | +226.3% | -5.1% | 287.7% | |
| LTM Mar 2026 | $57.73M | +12.7% | +11.7% | 25658.2% | |
| LTM Mar 2026 | $42.1M | +263.6% | — | 60.8% | |
| LTM Mar 2026 | $24.66M | +9371.4% | +212.3% | 147.5% | |
| LTM Dec 2025 | $22.66M | -42.6% | +198.4% | 174.0% | |
| LTM Mar 2026 | $7.05M | +49.8% | +31.2% | 62.9% | |
| LTM Mar 2026 | $6.95M | -211.1% | — | 15.7% | |
| LTM Mar 2026 | $569K | -68.7% | +48.1% | 4.1% | |
| LTM Mar 2026 | $348K | -99.4% | -8.7% | 0.3% | |
| Peer median (excluding HCAT) | $23.66M | +31.2% | +39.6% | 105.2% | |
Competitors are the stored peer set for HCAT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (153.21M) | (137.4M) | (118.15M) | (69.5M) | (177.97M) |
| Depreciation & Amortization | 37.53M | 48.3M | 42.22M | 41.43M | 50.5M |
| Deferred Income Tax | (7.13M) | (4.52M) | 8K | 77K | 81K |
| Stock-Based Compensation | 65.15M | 72.1M | 55.76M | 40.13M | 27.01M |
| Change in Working Capital | 4.62M | (13.91M) | (13.67M) | (660K) | (15.11M) |
| Accounts Receivables | 102K | 788K | (13.66M) | 4.28M | (1.81M) |
| Inventory | (8.33M) | 0 | 0 | 0 | 0 |
| Accounts Payables | 5.2M | (4.7M) | 4.87M | 5.58M | (11.51M) |
| Other Working Capital | 7.64M | (9.99M) | (4.88M) | (10.52M) | (1.79M) |
| Other Non-Cash Items | 29.93M | 162K | 750K | 3.09M | 116.22M |
| Operating Cash Flow | (23.12M) | (35.27M) | (33.08M) | 14.56M | 731K |
| Capital Expenditures | (18.47M) | (17.41M) | (14.31M) | (16.4M) | (968K) |
| Acquisitions (Net) | (46.76M) | (27.85M) | (11.39M) | (80.28M) | (41.11M) |
| Purchases of Investments | (261.36M) | (308.96M) | (290.84M) | (168.31M) | (65.13M) |
| Sales of Investments | 186.89M | 315.17M | 336.8M | 242.07M | 163.95M |
| Other Investing Activities | 22K | (15.22M) | (13.04M) | (14.77M) | (20.54M) |
| Investing Cash Flow | (139.68M) | (39.02M) | 20.29M | (22.9M) | 36.19M |
| Debt Repayment | 0 | 0 | 0 | 151.32M | (232.29M) |
| Common Stock Issued | 245.18M | 0 | 0 | 2.58M | 1.51M |
| Common Stock Repurchased | 0 | (8.39M) | (1.81M) | 0 | (5M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 18.9M | 5.78M | 4.54M | (2.15M) | 0 |
| Financing Cash Flow | 264.08M | (2.61M) | 2.73M | 151.75M | (235.78M) |
| Effect of Forex Changes | (10K) | (11K) | 21K | (34K) | 27K |
| Net Change in Cash | 101.27M | (76.92M) | (10.04M) | 143.37M | (198.83M) |
| Free Cash Flow | (41.59M) | (52.68M) | (47.39M) | (1.84M) | (237K) |
Health Catalyst, Inc.
NASDAQ:HCAT
Intrinsic Alpha fair value
Locked
Current Price
$1.29
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.